Life Science Investing Longer-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLC 07 September
Life Science Investing Summit Therapeutics to Host Update Call at WCLC 2025 on September 8, 2025 03 September
